Comparative Pharmacology
Head-to-head clinical analysis: PAPA DEINE 4 versus PERCODAN DEMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAPA DEINE 4 versus PERCODAN DEMI.
PAPA-DEINE #4 vs PERCODAN-DEMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: centrally acting analgesic and antipyretic, inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Codeine: opioid agonist, binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain.
Oxycodone is a full mu-opioid receptor agonist; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
1 tablet (oxycodone 2.25 mg/aspirin 325 mg) orally every 6 hours as needed for pain; maximum 4 tablets in 24 hours.
None Documented
None Documented
2-4 hours. In hepatic or renal impairment, half-life may increase to 4-6 hours, requiring dose adjustment.
Oxycodone: 3-4 hours; salicylate (aspirin): 2-3 hours at low doses, 15-30 hours at high doses; terminal half-life clinically relevant for dosing interval (q4-6h).
Renal: ~90% (70% as glucuronide conjugates, 10% as morphine, 10% as normorphine). Biliary/fecal: ~10%.
Renal: ~90% (oxycodone: ~60% as metabolites, ~10% unchanged; aspirin: ~80% as salicylates, ~10% unchanged). Biliary/fecal: minor.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination